特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
359839

ヘパラナーゼ:パイプライン分析

Heparanase - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 58 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ヘパラナーゼ:パイプライン分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 58 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、ヘパラナーゼを標的とする薬剤の適応症、開発段階、作用機序、投与経路および分子タイプ別の分析、薬剤の薬理作用に関する記述、これまでの研究開発動向、最新のニュースや発表、薬剤の開発に従事している主な企業の概要、休止/中止されたプロジェクトの情報などをお届けします。

イントロダクション

  • 調査範囲

ヘパラナーゼの概要

治療薬の開発

ヘパラナーゼ:開発中の製品 - 開発段階別

ヘパラナーゼ:開発中の製品 - 治療範囲別

ヘパラナーゼ:開発中の製品 - 適応症別

ヘパラナーゼ:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

ヘパラナーゼ:企業で開発中の製品

ヘパラナーゼ:大学/機関で開発中の製品

ヘパラナーゼ:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

ヘパラナーゼの治療薬開発に従事している企業

  • Momenta Pharmaceuticals, Inc.
  • Progen Pharmaceuticals Limited
  • Sigma-Tau S.p.A.

薬剤プロファイル

ヘパラナーゼ:休止中のプロジェクト

ヘパラナーゼ:開発が中止された製品

ヘパラナーゼ:主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Actavalon Inc, H2 2020
  • Pipeline by Active Biotech AB, H2 2020
  • Pipeline by Ampio Pharmaceuticals Inc, H2 2020
  • Pipeline by AnTolRx Inc, H2 2020
  • Pipeline by Bayer AG, H2 2020
  • Pipeline by Dermavant Sciences Inc, H2 2020
  • Pipeline by Hercules Pharmaceuticals BV, H2 2020
  • Pipeline by Hutchison MediPharma Ltd, H2 2020
  • Pipeline by Ikena Oncology Inc, H2 2020
  • Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
  • Pipeline by Magenta Therapeutics Inc, H2 2020
  • Pipeline by Pfizer Inc, H2 2020
  • Pipeline by Phenex Pharmaceuticals AG, H2 2020
  • Pipeline by Shenogen Pharma Group Ltd, H2 2020
  • Pipeline by Sol-Gel Technologies Ltd, H2 2020
  • Pipeline by Welichem Biotech Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
目次
Product Code: GMDHC2621TDB

Summary:

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase - Pipeline Review, H2 2020, outlays comprehensive information on the Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Heparanase is an endoglycosidase which cleaves heparan sulfate (HS) and hence participates in degradation and remodeling of the extracellular matrix (ECM). Heparanase is preferentially expressed in human tumors and its over-expression in tumor cells. The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also non-enzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K- and p38-dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent pro-angiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Ophthalmology and Immunology which include indications Coronavirus Disease 2019 (COVID-19), Retinopathy, Breast Cancer, Dry (Atrophic) Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Solid Tumor and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
  • The report reviews Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Overview
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Companies Involved in Therapeutics Development
  • Beta Therapeutics Pty Ltd
  • CarboMimetics
  • HepaRx Ltd
  • Leadiant Biosciences Inc
  • Momenta Pharmaceuticals Inc
  • Shenzhen Hepalink Pharmaceutical Group Co Ltd
  • Zucero Therapeutics Ltd
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Drug Profiles
  • Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Bone Marrow Transplant Rejection and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BT-2180 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CM-30119 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • H-1710 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • necuparanib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pixatimod - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Polysaccharides to Inhibit Heparanase for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • roneparstat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit Heparanase for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Heparanase for Inflammatory Diseases and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Heparanase for Type 1 and Type 2 Diabetes and Age Related Macular Degeneration - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit HPSE and VEGF for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Dormant Products
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Discontinued Products
  • Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.